From Inflammaging Theory to Bedside Conversation
For decades, inflammaging—the concept that chronic, low-grade inflammation quietly accelerates aging—has largely lived in research papers rather than clinics. That is starting to change. GlycanAge, a biological age-testing company, is convening leading scientists and clinicians this June in Dubrovnik for a landmark conference designed to convert 25 years of inflammaging research into clinical practice. The event, held under the International Society for Applied Biological Sciences (ISABS) series and co-organized with Mayo Clinic, is structured around a dedicated “clinical application day” focused on how doctors can use inflammation biology in everyday care. The core idea is that aging may start in the blood long before symptoms appear, with subtle immune changes signaling increased risk for conditions like heart disease, diabetes and stroke. By centering the meeting on real-world workflows rather than theory, organizers aim to make inflammaging relevant to primary care, preventive medicine and longevity-focused practices.
Glycan Testing and the Promise of Biological Age Measurement
At the heart of this shift is glycan testing biological age. Glycans—small sugar molecules attached to proteins—act like molecular switches that modulate immune responses. GlycanAge analyzes glycans on immunoglobulin G (IgG) in blood to infer whether the immune system is trending toward a pro-inflammatory or protective state. According to the company, specific glycan patterns can change up to a decade before a person develops diabetes, heart attack, stroke or other chronic conditions, opening the door to earlier interventions while patients still feel well. This represents a fundamental evolution in biological age measurement: instead of focusing only on chronological years or late-stage biomarkers, clinicians could track immune-related glycan signatures that reflect the body’s underlying inflammatory load. If broadly validated, this approach could turn inflammaging clinical applications into routine tools for stratifying risk and guiding lifestyle or therapeutic strategies long before overt disease emerges.
Institutional Backing Signals a Clinical Turning Point
The co-organization of the GlycanAge conference with Mayo Clinic is an important signal that glycan-based biological age measurement is moving beyond niche longevity circles. By embedding the meeting within the established ISABS conference framework, organizers are deliberately targeting mainstream clinicians, not just aging biology specialists. The agenda is expected to tackle practical questions: how to interpret glycan reports in the context of standard labs, how to communicate abstract risk to asymptomatic patients and how inflammaging markers fit alongside traditional cardiovascular or metabolic risk scores. This institutional backing also underscores that inflammaging clinical applications are being taken seriously as a potential diagnostic category rather than an experimental curiosity. If hospitals and large medical centers begin to explore IgG glycan quantification, it could accelerate regulatory discussions, reimbursement pathways and the integration of glycan analysis into standard preventive care protocols.
Absolute IgG Glycan Quantification: A New Benchmark for Aging Biomarkers
Parallel to these clinical efforts, researchers at Fudan University have introduced a powerful new way to quantify IgG glycans that could strengthen glycan testing for biological age. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and external glycan standards, they achieved absolute quantification of aging-associated IgG N-glycans in mice, rather than the relative measurements common in earlier work. Two structures stood out: GP3, a bisected glycan that declines with age, and GP8, a digalactosylated glycan that increases from early adulthood. These data were combined into the abGlycoAge index, a metric that translates precise IgG glycan concentrations into a biological age estimate. The index tracked known lifespan-extending interventions such as caloric restriction, indicating a younger biological state, and proved sensitive to molecular changes in glycosylation pathways. This level of rigor strengthens the case for IgG glycan quantification as a robust, reproducible aging biomarker.
From Biomarkers to Interventions: What Comes Next for Glycan-Based Aging Tools
The emerging convergence between conferences like GlycanAge’s and lab advances such as the abGlycoAge index points toward a new generation of inflammaging clinical applications. The Fudan team’s glycoengineering experiments, in which aged mice received IgG engineered with more youthful glycan patterns, showed reductions in inflammatory cytokines and markers of cellular senescence, hinting that glycans might become not just diagnostic tools but therapeutic levers. For clinicians, however, the immediate horizon is more about measurement than intervention: incorporating glycan-based biological age testing into risk assessments, using results to motivate lifestyle changes and monitoring how glycan profiles respond to diet, exercise or pharmacologic strategies. As evidence accumulates and institutional players stay engaged, glycan analysis is poised to shift aging research from theory toward implementable clinical diagnostics, allowing doctors and patients to see—and potentially modify—biological age years before disease surfaces.